Post by
askretka on May 16, 2022 2:46pm
More Keytruda vs Opdivo competition
Staying in the back seat to Keytruda, Bristol Myers reports another pivotal setback in urothelial cancer.. ----------------- Just a few weeks after Bristol Myers Squibb and Nektar put the kibosh to their combo study of Opdivo and bempeg for metastatic urothelial cancer, one of the last big flameouts that convinced the pharma giant to squash their multibillion-dollar alliance, Bristol Myers is back with more bad news for the field. Bumping into fresh trouble trying to move into a bigger position in frontline therapy, Bristol Myers reported that their Opdivo/Yervoy combo flopped in a Phase III study of first-line therapy for previously untreated patients with the most common form of bladder cancer. We dont know the hard numbers yet, but the study Checkmate-901 failed to hit on overall survival. Once again, Bristol Myers is taking a loss on their drug while market-leader Keytruda moves forward, although not always so smoothly. --------------------------- I see this as a possible win/win for the Future. BMS wants to do a deal with us to compete with Merck's Keytruda or Merck wants us as a bolt on too keep ahead of BMS. Cheers!!!!
Comment by
Noteable on May 16, 2022 8:54pm
I don't think that BMS is looking at ONCY since BMS is already tied to another oncolytic virus through a 2016 deal with PsiOxus.